LIGAND PHARMACEUTICALS INC — Director's Dealing 2021

Aug 5, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: LIGAND PHARMACEUTICALS INC (LGND)
CIK: 0000886163
Period of Report: 2021-08-04

Reporting Person: FOEHR MATTHEW W (President and COO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-04	Common Stock	M	8840	$21.92	Acquired	173195	Direct
2021-08-04	Common Stock	S	8840	$109.6727	Disposed	164355	Direct
2021-08-04	Common Stock	M	1142	$85.79	Acquired	165497	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-08-04	Employee Stock Option (right to buy)	$21.92	M	8840	Disposed	2023-02-15	Common Stock (8840)	Direct
2021-08-04	Employee Stock Option (right to buy)	$85.79	M	1142	Disposed	2026-02-11	Common Stock (1142)	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.06 to $111.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

F2: Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.

F3: Grant to reporting person of options to purchase shares of common stock ("Option Shares"), exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/11/16.